Combination chemotherapy with cisplatin, carboplatin, and etoposide in advanced malignancy: A phase I trial

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 20, Issue 5, 1997, Pages 500-504

  Vincent Rajkumar, S ^a   Frytak, Stephen ^a   Rubin, Joseph ^a   Camoriano, John K ^b   Fitch, Tom R ^b  

^a MAYO CLINIC   (United States)

^b MAYO CLINIC   (United States)

Author keywords

Advanced malignancy; Carboplatin; Chemotherapy; Cisplatin; Etoposide

Indexed keywords

CARBOPLATIN; CISPLATIN; ETOPOSIDE;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; DOSE RESPONSE; DRUG POTENTIATION; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LEUKOPENIA; MALE; NEPHROTOXICITY; OTOTOXICITY; PHASE 1 CLINICAL TRIAL; THROMBOCYTOPENIA;

ADENOCARCINOMA; ADULT; AGED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CAUSE OF DEATH; CISPLATIN; CLINICAL TRIALS, PHASE II; COCHLEA; DIGESTIVE SYSTEM NEOPLASMS; DRUG ADMINISTRATION SCHEDULE; DRUG SYNERGISM; ESOPHAGEAL NEOPLASMS; ETOPOSIDE; EVALUATION STUDIES; FEMALE; HUMANS; KIDNEY; LEUKOPENIA; LUNG NEOPLASMS; MALE; MIDDLE AGED; NAUSEA; NEUTROPENIA; REMISSION INDUCTION; SEPSIS; STOMACH NEOPLASMS; THROMBOCYTOPENIA; VOMITING;

EID: 0030769555     PISSN: 02773732     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000421-199710000-00013     Document Type: Article

References (29)

1. Lyss AP. Enzymes and random synthetics. In: Perry MC, ed. The chemotherapy source book. Baltimore: Williams & Wilkins, 1992:405-11.
2. Knox RJ, Freidlos F, Lydall DA, Roberts JJ. Mechanism of cytotoxicity of anticancer platinum drugs: evidence that cisdiamminedichloroplatinum (II) and cis-diammine (1,1,cyclobutanedicarboxylate) platinum (II) differ in their kinetics with DNA. Cancer Res 1986;46:1972-9.
3. Micetich KC, Barnes D, Erickson LC. A comparative study of cytotoxicity and DNA effects of cis (diammino) (l,l,cyclobutane-dicarboxylate) platinum (II) and cis-diammine-dichloroplatinum (II) on L1210 cells. Cancer Res 1985;45:4043-7.
4. Reed E, Kohn KW. Platinum analogues. In: Chabner BA, Collins JM, eds. Cancer chemotherapy: principles and practice. Philadelphia: J.B. Lippincott, 1990:465-90.
5. Hannigan EV, Green S, Alberts DS, O'Toole R, Surwit E. Results of a Southwest Oncology Group phase III trial of carboplatin plus cyclophosphamide versus cisplatin plus cyclophosphamide in advanced ovarian cancer. Oncology 1993;50(suppl 2):2-9.
6. Swenerton K, Jeffrey J, Stuart G. Cisplatin-cyclophosphamide versus carboplatin-cyclophosphamide in advanced ovarian cancer. A randomized phase III study of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 1992; 10:718-26.
7. Ozols RF, Corden BJ, Jacob J, Wesley MN, Ostchega Y, Young RC. High dose cisplatin in hypertonic saline. Ann Intern Med 1984; 100:19-24.
8. Ozols RF, Ostchega Y, Myers CE, Young RC. High dose cisplatin in Hypertonie saline in refractory ovarian cancer. J Clin Oncol 1985;3:I246-50.
9. Samson MK, Rivkin SE, Jones SE, et al. Dose response and dose survival advantage for high versus low dose cisplatin combined with vinblastine and bleomycin in disseminated testicular cancer. A Southwest Oncoloey Group study. Cancer 1984; 53:1029-35.
10. Levin L, Hryniuk WM. Dose intensity analysis of chemotherapy regimens in ovarian carcinoma. J din Oncol 1987;5:756-67.
11. Ozols RF, Ostchega Y, Curt G, Young RC. High dose carboplatin in refractory ovarian cancer. J Clin Oncol 1987:5:197-201.
12. Gore ME, Calvert AH, Smith LE. High dose carboplatin in treatment of lung cancer and mesothelioma. A phase I dose escalation study. Ear J Cancer Clin Oncol 1987;23:1391-7.
13. Shea TC, Flaherty M, Elias A, et al. A phase I clinical and pharmacokinetic study of carboplatin and autologous bone marrow support. J Clin Oncol 1989; 7:651-61.
14. Gill I, Muggia FM, Terheggen PM, et al. Dose escalation study of carboplatin (day 1) and cisplatin (day 3): tolerance and relation to leukocyte and buccal platinum-DNA adducts. Ann Oncol 1991;2:115-21.
15. Segelov E, Stuart-Harris R, Bell D, Tattersali M, Hutton-Potts J, Friedlander M. A phase II study of carboplatin and cisplatin in advanced ovarian cancer. EnrJ Gynecol Oncol 1994; 15:277-82.
16. Morris M, Gershenson DM, Burke TW. A phase II study of carboplatin and cisplatin in advanced or recurrent squamous cell carcinoma of the uterine cervix. Gynecol Oncol 1994;53:234-8.
17. Leger-Enreille A, Curé H, Pezet D, Bargnoux PJ. Pharmacokinetic study in carboplatin, cisplatin and 5-fluorouracil regimen for advanced esophageal cancer. Anticancer Res 1994; 14:2327-9.
18. O'Dwyer PJ, Leyland-Jones B, Alonso MT, et al. Etoposide (VP-16-213): current status of an active anticancer drug. N Engl J Meil 1985;3I2:692-700.
19. Donehower RC, Rowinsky EK. Anticancer drugs derived from plants. In: DeVita VT, Hellman S, Roseberg SA, eds. Cancer: principles and practice of oncology, 4th ed. Philadelphia: J. B. Lippincott; 1993:412-4.
20. Longeval E, Klastersky J. Combination chemotherapy with cisplatin and etoposide in bronchogenic squamous cell carcinoma and adenocarcinoma. A study by the EORTC lung cancer working party (Belgium). Cancer 1982;50:2751-6.
21. Smith IE, Evans BD, Gore ME, et al. Carboplatin (Paraplatin; JM8) and etoposide (VP-16) as first line combination therapy for small-cell lung cancer. J Clin Oncol 1987;5:185-9.
22. Cox EB, Burton GV, Olson GA, Vugrin D. Cisplatin and etoposide: an effective treatment for refractory breast carcinoma. Am J Clin Oncol 1989; 12:53-6.
23. Einhorn LH, Williams SD, Loehrer PJ, et al. Evaluation of optimal duration of chemotherapy in favorable prognosis disseminated germ cell tumors: a Southeastern Cancer Study Group protocol. J Clin Oncol 1989;7:387-9I.
24. Creagan ET, Richardson RL, Kovach JS. Pilot study of a continuous intravenous infusion of etoposide concomitant with cisplatin in selected patients with advanced cancer. J Clin Oncol 1988;6:1197-201.
25. Eagan RT, Fleming TR, Schoonover V. Evaluation of response criteria in advanced lung cancer. Cancer 1979;44:1125-8.
26. Sculier JP, Klastersky J, Giner V, et al. Phase II randomized trial comparing high dose cisplatin with moderate dose cisplatin and carboplatin in patients with advanced non small cell lung cancer. European Lung Cancer Working Party. J Clin Oncol 1994; 12:353-9.
27. Saito H, Shimokata K, Saka H, et al. Phase II study of carboplatin, cisplatin, and vindesine in advanced non-small-cell lung cancer. Cancer Cliemollier Pharmacol 1993;33:154-6.
28. Ardizzoni A, Addamo GF, Baldini E, et al. Mitomycin-ifosfamide-cisplatinum (MIP) vs MIP-interferon vs cisplatinum-carboplatin in metastatic cancer: a FONICAP randomized phase II study. Italian Lung Cancer Task Force. Br J Cancer 1995; 71:115-9.
29. Filtenborg TA, Hansen HH, Aage Engelholm S, Rorth M. A phase II study of ifosfamide, carboplatin and cisplatin in advanced and recurrent squamous cell carcinoma of the uterine cervix. Ann Oncol 1993:4:485-8.